ArticleBioconjugate chemistry
Development of contrast agents targeted to macrophage scavenger receptors for MRI of vascular inflammation.
Article in Bioconjugate chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Neuroinflammation in the Evolution of Motor Function in Stroke and Trauma Patients: Treatment and Potential Biomarkers.Current issues in molecular biology · 2023Review
- Tracking macrophages in diabetic neuropathy with two-color nanoemulsions for near-infrared fluorescent imaging and microscopy.Journal of neuroinflammation · 2021Article
- Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy.Nanoscale horizons · 2021Review
- Towards Photoswitchable Contrast Agents for Absolute 3D Temperature MR Imaging.Angewandte Chemie (International ed. in English) · 2021Article
- Human serum albumin-based probes for molecular targeting of macrophage scavenger receptors.International journal of nanomedicine · 2019Article
- Peripheral Nerve Nanoimaging: Monitoring Treatment and Regeneration.The AAPS journal · 2017Review
- Quantitative assessment of binding affinities for nanoparticles targeted to vulnerable plaque.Bioconjugate chemistry · 2015Article
- Multimodality PET/MRI agents targeted to activated macrophages.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2014Article
- Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging.Current molecular imaging · 2012Article
- Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques.Biomaterials · 2011Article
- Noninvasive cell-tracking methods.Nature reviews. Clinical oncology · 2011Review
- Novel method to label solid lipid nanoparticles with 64cu for positron emission tomography imaging.Bioconjugate chemistry · 2011Article
- PET Imaging and Biodistribution of Silicon Quantum Dots in Mice.ACS medicinal chemistry letters · 2011Article
- Characterization and in vitro and in vivo testing of CB2-receptor- and NGAL-targeted paramagnetic micelles for molecular MRI of vulnerable atherosclerotic plaque.Molecular imaging and biology · 2010Article
- Article
- Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.Chemical reviews · 2010Review
- Paramagnetic, silicon quantum dots for magnetic resonance and two-photon imaging of macrophages.Journal of the American Chemical Society · 2010Article
- Bioresponsive, cell-penetrating, and multimeric MR contrast agents.Accounts of chemical research · 2009Article
- Synthesis of 64Cu-labeled magnetic nanoparticles for multimodal imaging.Bioconjugate chemistry · 2008Article
- Simultaneous in vivo positron emission tomography and magnetic resonance imaging.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Atherosclerosis is a leading cause of death in the U.S. Because there is a potential to prevent coronary and arterial disease through early diagnosis, there is a need for methods to image arteries in the subclinical stage as well as clinical stage using various noninvasive techniques, including magnetic resonance imaging (MRI). We describe a development of a novel MRI contrast agent targeted to plaques that will allow imaging of lesion formation. The contrast agent is directed to macrophages, one of the earliest components of developing plaques. Macrophages are labeled through the macrophage scavenger receptor A, a macrophage specific cell surface protein, using an MRI contrast agent derived from scavenger receptor ligands. We have synthesized and characterized these contrast agents with a range of relaxivities. In vitro studies show that the targeted contrast agent accumulates in macrophages, and solution studies indicate that micromolar concentrations are sufficient to produce contrast in an MR image. Cell toxicity and initial biodistribution studies indicate low toxicity, no detectable retention in normal blood vessels, and rapid clearance from blood. The promising performance of this contrast agent targeted toward vascular inflammation opens doors to tracking of other inflammatory diseases such as tumor immunotherapy and transplant acceptance using MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.